1,241 HCA Healthcare, Inc. $HCA Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 46.7% during the third quarter, HoldingsChannel reports. The firm owned 1,415 shares of the company’s stock after selling 1,241 shares during the quarter. D.A. Davidson & CO.’s holdings in HCA Healthcare were worth $604,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HCA. BlackRock Inc. acquired a new position in HCA Healthcare in the second quarter valued at about $5,069,974,000. Legal & General Group Plc purchased a new stake in HCA Healthcare during the second quarter worth approximately $410,992,000. Jupiter Topco LLC acquired a new stake in HCA Healthcare during the second quarter valued at approximately $371,138,000. Wellington Management Group LLP boosted its stake in HCA Healthcare by 20.5% during the 2nd quarter. Wellington Management Group LLP now owns 4,707,473 shares of the company’s stock valued at $1,835,397,000 after purchasing an additional 799,761 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of HCA Healthcare in the 2nd quarter valued at approximately $238,457,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Investors have welcomed expectations that a Democratic-controlled Congress could provide a policy tailwind for hospitals. However, the anticipated relief is not yet enacted and still depends on legislative and funding steps. HCA Healthcare Gains Policy Tailwind
• Positive Sentiment: HCA is expanding AI tools, with its nurse handoff technology heading to 100 hospitals and ambient AI expected to reach 10,000 physicians by year-end. These deployments could support workflow efficiency. AI nurse handoff tool
• Positive Sentiment: Analyst and technical coverage is supportive: Truist reaffirmed its Buy rating, while Zacks highlighted earnings growth, price strength and a bullish moving-average signal. Truist reaffirms Buy rating Zacks stock outlook
• Neutral Sentiment: HCA completed a $6.5 billion senior notes offering. The report confirms the financing but gives limited detail on its use or effect on borrowing costs. Senior notes offering
• Neutral Sentiment: HCA’s AI chief emphasized that delaying a rollout can be appropriate, suggesting a measured approach that may limit near-term adoption while managing implementation risks. HCA AI rollout strategy
• Negative Sentiment: One report flagged potential payer pressure in HCA’s 2027 outlook, a concern for future hospital reimbursement and margins. Payer pressure outlook
• Negative Sentiment: Pomerantz LLP said it is investigating investor claims involving HCA. The announcement provides no findings, but the inquiry may create a legal overhang. Investor investigation announcement

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HCA shares. Leerink Partners reaffirmed an “outperform” rating and issued a $492.00 target price on shares of HCA Healthcare in a report on Friday, September 18th. JPMorgan Chase & Co. decreased their price target on shares of HCA Healthcare from $490.00 to $425.00 and set a “neutral” rating on the stock in a research report on Thursday, August 20th. Oppenheimer reduced their target price on shares of HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating for the company in a report on Monday, July 27th. The Goldman Sachs Group lowered their price target on shares of HCA Healthcare from $558.00 to $485.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of HCA Healthcare in a research note on Wednesday, July 15th. Sixteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $480.13.

HCA Healthcare Price Performance

NYSE:HCA opened at $494.44 on Friday. HCA Healthcare, Inc. has a one year low of $353.99 and a one year high of $556.52. The company has a market cap of $103.28 billion, a PE ratio of 16.38, a P/E/G ratio of 1.56 and a beta of 1.11. The firm’s 50 day simple moving average is $443.66 and its 200 day simple moving average is $445.25.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Tuesday, October 27th. The company reported $7.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.65 by $0.57. The firm had revenue of $19.85 billion for the quarter, compared to analysts’ expectations of $19.33 billion. HCA Healthcare had a net margin of 8.61% and a negative return on equity of 198.52%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.96 earnings per share. Equities research analysts expect that HCA Healthcare, Inc. will post 30.15 EPS for the current year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 29th. Investors of record on Tuesday, December 15th will be paid a $0.78 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.34%.

Insider Transactions at HCA Healthcare

In other news, COO Jon Foster sold 21,713 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $494.95, for a total transaction of $10,746,849.35. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $4,949,500. This represents a 68.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael J. Schlosser sold 1,200 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $494.65, for a total transaction of $593,580.00. Following the transaction, the executive vice president directly owned 1,443 shares in the company, valued at approximately $713,779.95. This trade represents a 45.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 32,913 shares of company stock worth $16,481,129 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

HCA Healthcare Company Profile

HCA Healthcare is a healthcare services company that operates hospitals and other care facilities. Its services include inpatient and outpatient care, emergency treatment, surgery, diagnostic services and specialized care across areas such as cancer and cardiovascular medicine.

The company serves patients in the United States and the United Kingdom through its network of hospitals and outpatient facilities, including surgery centers, urgent care clinics and physician practices.

Founded in 1968, HCA Healthcare is headquartered in Nashville, Tennessee.